


Drospirenone-d4-1

Cat. No.:	HY-B0111S1
Molecular Formula:	C ₂₄ H ₂₆ D ₄ O ₃
Molecular Weight:	370.52
Target:	Progesterone Receptor
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Drospirenone-d4-1 is deuterium labeled Drospirenone.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Fuhrmann, U., et al., The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. *Contraception*, 1996. 54(4): p. 243-51.
- [3]. Muhn, P., et al., Drospirenone: a novel progestogen with antiminerlocorticoid and antiandrogenic activity. *Pharmacological characterization in animal models.* *Contraception*, 1995. 51(2): p. 99-110.
- [4]. Warming, L., et al., Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. *Climacteric*, 2004. 7(1): p. 103-11.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA